DURECT (DRRX)
(Delayed Data from NSDQ)
$1.67 USD
-0.01 (-0.30%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $1.67 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
DURECT Corporation [DRRX]
Reports for Purchase
Showing records 41 - 60 ( 143 total )
Company: DURECT Corporation
Industry: Medical - Drugs
We are initiatng coverage with a Buy rating and 12-month Price Target of $7/share
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: DURECT Corporation
Industry: Medical - Drugs
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Program for Our Fourth Annual Virtual NASH Investor Conference, October 5
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Phase 2b AH Trial Designed to Support Full Approval; Phase 2 COVID-19 Trial Has Strong Rationale Too; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Company: DURECT Corporation
Industry: Medical - Drugs
2Q20 Results; AVB-500 Moves Forward in PROC and ccRCC on Solid Footing
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
DURECT Kicks off DUR-928 Study in COVID-19 Patients With Acute Liver or Kidney Injury; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ABBOTT G
Company: DURECT Corporation
Industry: Medical - Drugs
The End of the Gilead Agreement Has No Impact on Our Model or Thesis; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
We View Positive Phase 1b NASH Data as Highly Supportive of Advancing Development; Rais
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
1Q20 Recap: DUR-928 Takes on COVID-19; Phase 2 Data Potentially by YE20; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
4Q19 Recap Expecting an Eventful Mid-2020 for DUR-928 in AH and NASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Psoriasis Failure a Non-Event; We Raise PT to $5.50 on Updated AH Model
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Taking a Closer Look at the Striking Results of DUR-928 in Alcoholic Hepatitis; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Expecting a Favorable Outcome From POSIMIR''s AdCom Meeting on January 16, 2020; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
3Q Recap: DUR-928 Offers Breakthrough Data for Alcoholic Hepatitis
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Final Program for Our Third Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Program for Our Third Annual NASH Investor Conference, October 21, New York
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Positive Data in Alcoholic Hepatitis Serve as First of Three Validation Points for DUR-928 in 2H19; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Recently Signed Gilead Partnership Yields First $10M Milestone; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: DURECT Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department